patient group direction

Size: px
Start display at page:

Download "patient group direction"

Transcription

1 NAPROXEN v01 1/10 NAPROXEN PGD Details Version 1.0 Legal category Staff grades Approved by POM Paramedic (Non-ECP) Nurse (Non-ECP) Emergency Care Practitioner (Paramedic) Emergency Care Practitioner (Nurse) Medicines Management Group Date issued 31/01/2013 Review date 30/01/2015 Clinical Publication Category Mandatory (RED) - No deviation from document permissible Clinical Requirements Competencies Continuing education Successful completion of a competency assessment in the use of this medicine for the indications stated; Completion of education in both the legal and professional aspects of PGD administration and the supply of medicines; Registered paramedics must have successfully completed a recognised Emergency Care Practitioner course; Registered nurses must be employed as Nurse Practitioners or have successfully completed a recognised Emergency Care Practitioner course. The clinician is responsible for keeping him/herself aware of any changes to the recommendations for the medicine listed. It is the responsibility of the individual to keep up-to-date with continued professional development and to work within the limitations of their own individual scope of practice.

2 NAPROXEN v01 2/10 Clinical Situation Clinical situation Inclusion criteria Exclusion criteria Management of acute musculoskeletal disorders and dysmenorrhoea; Management of pain and inflammation in acute gout. Adults & children 16 years and over with acute musculoskeletal disorders and dysmenorrhoea; Adults over 16 years of age with pain and inflammation in acute gout. Patients with a hypersensitivity to naproxen or any other NSAID (including those in whom attacks of asthma, angioedema, urticaria or rhinitis have been precipitated by aspirin or any other NSAID); Asthmatic patients who have never taken an NSAID; Pregnancy; Breast-feeding; Women undergoing investigation for infertility or attempting to conceive; Patients with coagulation defects (decreases platelet aggregation and increases bleeding time); Severe heart failure; Previous or active peptic ulceration; Children <16years; Moderate or severe renal impairment; Severe liver disease (liver enzymes 3x upper limit of normal); Hypovolaemia or dehydration; Porphyria; Patients already taking: NSAIDs (check OTC use); Lithium; Corticosteroids; Anti-coagulants; Clopidogrel; Ciclosporin; Methotrexate; Tacrolimus; SSRIs; Quinolone antibiotics; Heparin.

3 NAPROXEN v01 3/10 Cautions CSM Warning (asthma): Any degree of worsening of asthma may be related to the ingestion of NSAIDS, either prescribed or (in the case of ibuprofen and others) purchased over the counter; CSM Advice (Aspirin 75mg): The combination of a NSAID and low dose aspirin may increase the risk of GI side-effects. This combination should only be used if absolutely necessary and the patient monitored closely; CSM advice (gastro-intestinal side-effects): All NSAIDS are associated with gastrointestinal toxicity; the risk is higher in the elderly. Evidence on the relative safety of 7 non-selective NSAIDS indicates differences in the risks of serious upper GI side-effects. Ibuprofen is associated with the lowest risk, naproxen with intermediate risk; Patients with hypertension should be treated with caution as naproxen may antagonise the effect of anti-hypertensive drugs by causing fluid retention and therefore increasing blood pressure; Naproxen may increase the plasma concentration of cardiac glycosides, e.g. digoxin; Aseptic meningitis has rarely been reported with NSAIDs. Patients with connective tissue disorders such as systemic lupus erythematosus may be especially susceptible; Naproxen may provoke renal failure in someone who is dehydrated especially if the person has diabetes; All patients greater than 65 years of age are at risk of an adverse event even in the absence of cardiovascular or renal risk factors; Excessive alcohol consumption, smoking and H. pylori infection are additional GI risk factors; Consider co-morbidity: Cardiovascular disease, renal disease (including dehydration), diabetes, hypertension and hepatic disease as they increase the risk of an adverse event; Naproxen may impair female fertility.

4 NAPROXEN v01 4/10 Side effects Action if excluded Action if patient declines Hypersensitivity reactions including skin rashes (common), angioedema and bronchospasm; Gastro-intestinal discomfort, nausea, diarrhoea and occasionally bleeding and ulceration. (NB Systemic as well as local effects contribute to GI damage); CNS toxicity including headache, dizziness, nervousness, depression, drowsiness, insomnia and vertigo; Hearing disturbances including tinnitus; Photosensitivity; Haematuria; Renal failure may be provoked especially in patients with renal impairment; Hepatic damage, alveolitis, eye changes, pancreatitis; Thirst, myalgia, pyrexia, muscle weakness; Female infertility. If patient meets exclusion criteria consider alternative pain management or /and refer to a medical practitioner if necessary; Record in patient clinical record the reason for exclusion and any action taken. If patient declines treatment or advice, ensure the patient clinical record details: The advice given by the clinician; Details of any referral made; The intended actions of the patient (including parent or guardian).

5 NAPROXEN v01 5/10 Description of Treatment Generic name Presentation Route Naproxen. 250mg tablets (EC). Oral. Method Administration Supply Dose Acute musculoskeletal disorders and dysmenorrhoea: 500mg (two tablets) initially followed by 250mg (one tablet) at six to eight hour intervals as needed. With a maximum daily dose after the first day of 1250mg (five tablets). Acute gout: 750mg at once then 250mg every eight hours until the attack has passed. Frequency Duration of treatment Quantity to supply See dose. Shortest duration necessary to control symptoms. 1 x 28 tablets; Ensure that each pack of medicine supplied is labelled with the patient s name, the date and the Trust s contact details.

6 NAPROXEN v01 6/10 Follow Up Referral arrangements and safety netting Advice to patients Records References Ensure that there is a communication to the patient s registered GP to inform him/her about the consultation, the outcomes of that consultation and any treatment given using local mechanisms. This information must also be available to other healthcare professionals who may be required to administer care to the patient following the consultation; If rash, bronchospasm or other signs of hypersensitivity occur, stop taking the medicine and contact your doctor for advice; Patients who experience dizziness or other CNS disturbances while taking naproxen should refrain from driving or operating machinery; Do not take other painkillers at the same time as taking this medicine without asking your doctor or pharmacist for advice; Seek further medical attention if symptoms persist or they deteriorate. Undesirable effects can be reduced by taking the lowest effect dose for the shortest duration necessary to control symptoms; Swallow tablets whole and take with or after food. Taking naproxen with food can reduce symptoms such as dyspepsia. Complete patient clinical record. British National Formulary 64, September 2012 (BNF); Clinical Knowledge Summaries nhs.uk.

7 NAPROXEN v01 7/10 Authorisation Chief Executive Officer Medical Director Pharmaceutical Advisor Name Ken Wenman Signature Date 01/02/2013 Name Dr Andy Smith Signature Date 01/02/2013 Name Sue Oakley Signature Date 01/02/2013 This must be signed by the Chief Executive Officer, Medical Director and Pharmaceutical Advisor to be legally valid.

8 NAPROXEN v01 8/10 Individual Authorisation (Staff Copy) Individual Name Signature Date / / Authorising officer Name Signature Date / / I have read and understood the Patient Group Direction and agree to supply this medicine only in accordance with this document. PGDs do not remove inherent professional obligations or accountability. It is the responsibility of each professional to practice only within the bounds of their own competence and in accordance with their own Code of Professional Conduct. This signed page must be retained by the member of staff, together with the full PGD, which must be available in clinical practice.

9 NAPROXEN v01 9/10 Individual Authorisation (Trust Copy) Individual Name Signature Date / / Authorising officer Name Signature Date / / I have read and understood the Patient Group Direction and agree to supply this medicine only in accordance with this document. PGDs do not remove inherent professional obligations or accountability. It is the responsibility of each professional to practice only within the bounds of their own competence and in accordance with their own Code of Professional Conduct. This signed page must be retained by the member of staff, together with the full PGD, which must be available in clinical practice.

10

patient group direction

patient group direction ASPIRIN v01 1/8 ASPIRIN PGD Details Version 1.0 Legal category P Staff grades Approved by Paramedic (Non-ECP) Nurse (Non-ECP) Emergency Care Practitioner (Paramedic) Emergency Care Practitioner (Nurse)

More information

patient group direction

patient group direction ACICLOVIR v01 1/8 ACICLOVIR PGD Details Version 1.0 Legal category Staff grades Approved by POM Paramedic (Non-ECP) Nurse (Non-ECP) Emergency Care Practitioner (Paramedic) Emergency Care Practitioner (Nurse)

More information

patient group direction

patient group direction CYCLIZINE v01 1/7 CYCLIZINE PGD Details Version 1.0 Legal category Staff grades Approved by POM Paramedic (Non-ECP) Nurse (Non-ECP) Emergency Care Practitioner (Paramedic) Emergency Care Practitioner (Nurse)

More information

patient group direction

patient group direction NITROFURANTOIN v01 1/12 NITROFURANTOIN PGD Details Version 1.0 Legal category Staff grades Approved by POM Paramedic (Non-ECP) Nurse (Non-ECP) Emergency Care Practitioner (Paramedic) Emergency Care Practitioner

More information

patient group direction

patient group direction DIAZEPAM v01 1/9 DIAZEPAM PGD Details Version 1.0 Legal category Staff grades Approved by CD Benz POM Paramedic (Non-ECP) Nurse (Non-ECP) Emergency Care Practitioner (Paramedic) Emergency Care Practitioner

More information

patient group direction

patient group direction SALBUTAMOL v01 1/12 SALBUTAMOL PGD Details Version 1.0 Legal category Staff grades Approved by POM Paramedic (Non-ECP) Nurse (Non-ECP) Emergency Care Practitioner (Paramedic) Emergency Care Practitioner

More information

Document Details. Ibuprofen 200mg tablets and Ibuprofen oral liquid 100mg in 5ml

Document Details. Ibuprofen 200mg tablets and Ibuprofen oral liquid 100mg in 5ml Title Document Details Patient Group Direction (PGD) Ibuprofen 200mg tablets and Ibuprofen oral liquid 100mg in 5ml Trust Ref No 1445-36348 Local Ref (optional) Main points the document The treatment of

More information

patient group direction

patient group direction REVAXIS v01 1/12 REVAXIS (DIPHTHERIA, TETANUS AND POLIOMYELITIS (INACTIVATED) VACCINE (ADSORBED, REDUCED ANTIGEN(S) CONTENT)) PGD Details Version 1.0 Legal category Staff grades Approved by POM Paramedic

More information

patient group direction

patient group direction DIAZEPAM (RECTAL) v01 1/8 DIAZEPAM (RECTAL) PGD Details Version 1.0 Legal category Staff grades Approved by POM Paramedic (Non-ECP) Nurse (Non-ECP) Emergency Care Practitioner (Paramedic) Emergency Care

More information

patient group direction

patient group direction PRESERVATIVE-FREE LIDOCAINE v1.0 1/9 PRESERVATIVE-FREE LIDOCAINE PGD Details Version 1.0 Legal category Staff grades Approved by POM Registered Paramedic Registered Nurse Medicines Management Group Date

More information

Patient Group Direction for the supply and/or administration of Ibuprofen 400mg tablets to patients attending NHS Borders services

Patient Group Direction for the supply and/or administration of Ibuprofen 400mg tablets to patients attending NHS Borders services Patient Group Direction for the supply and/or administration of Ibuprofen 400mg tablets to patients attending NHS Borders services This document authorises the supply and/or administration of Ibuprofen

More information

patient group direction

patient group direction MORPHINE SULPHATE (Oral) v01 1/8 MORPHINE SULPHATE (Oral) PGD Details Version 1.0 Legal category Staff grades Approved by POM Paramedic (Non-ECP) Nurse (Non-ECP) Emergency Care Practitioner (Paramedic)

More information

Patient Group Direction for Doxycycline (Tetracycline) Version: 01 Start Date: October 2015 Expiry Date: October 2018

Patient Group Direction for Doxycycline (Tetracycline) Version: 01 Start Date: October 2015 Expiry Date: October 2018 THIS PATIENT GROUP DIRECTION HAS BEEN AGREED BY THE FOLLOWING ORGANISATIONS: CLINICAL COMMISSIONING GROUP: Doncaster CCG Lancashire North CCG Fylde & Wyre CCG East Lancashire CCG Change history Version

More information

Elements for a Public Summary Overview of disease epidemiology

Elements for a Public Summary Overview of disease epidemiology VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Acute pain usually responds to medication and should settle in less than three months. Inadequate pain relief may lead to other

More information

Children Enteric coated tablet : 1-3 mg/kg per day in divided doses.

Children Enteric coated tablet : 1-3 mg/kg per day in divided doses. Ultrafen Tablet/SR Tablet/Suppository/Gel Description Ultrafen is a preparation of Diclofenac is a non-steroidal antiinflammatory agent with marked analgesic, anti-inflammatory and antipyretic properties.

More information

for adults engaged with the Family Wellbeing Service Isle of Wight In Community Pharmacy for Isle of Wight Public Health Commissioned Services

for adults engaged with the Family Wellbeing Service Isle of Wight In Community Pharmacy for Isle of Wight Public Health Commissioned Services The supply of Champix (Varenicline) Tablets 500mcg and 1mg by registered community pharmacists for smoking cessation / management of nicotine withdrawal for adults engaged with the Family Wellbeing Service

More information

PATIENT GROUP DIRECTION

PATIENT GROUP DIRECTION PATIENT GROUP DIRECTION Supply / Administration of: By: Pharmacists Azithromycin 250mg capsules for Chlamydia In: Community Pharmacy It is the responsibility of the professional working under this PGD

More information

Patient Group Direction (PGD)

Patient Group Direction (PGD) Patient Group Direction (PGD) Supply of Nitrofurantoin for uncomplicated Urinary Tract Infections in females aged 16 years and over (Telford and Wrekin and Shropshire Pharmacies Only) For the supply of

More information

Continence PGD transdermal oxybutynin Kentera patch 36mg

Continence PGD transdermal oxybutynin Kentera patch 36mg Continence PGD transdermal oxybutynin Kentera patch 36mg Patient group direction for the supply of transdermal oxybutynin Kentera patch 36mg to patients suffering from urinary frequency, urgency or incontinence

More information

Document Details. Patient Group Direction

Document Details. Patient Group Direction Document Details Title Patient Group Direction (PGD) Salbutamol Aerosol Inhaler and salbutamol Nebulised Solution Trust Ref No 1569-34313 Local Ref (optional) Main points the document Treatment of acute

More information

PROFESSIONAL INFORMATION

PROFESSIONAL INFORMATION SCHEDULING STATUS: S1 PROPRIETARY NAME AND DOSAGE FORM: Aleve Tablets COMPOSITION: Each tablet contains naproxen sodium 220 mg (equivalent to 200 mg naproxen) CATEGORY AND CLASS: A / 2.7 Antipyretic or

More information

Expiry Date: September 2009 Template Version: Page 1 of 7

Expiry Date: September 2009 Template Version: Page 1 of 7 GG&C PGD ref 2007/467 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: Inclusion criteria: Exclusion criteria:

More information

Medicines Protocol RECTAL DIAZEPAM

Medicines Protocol RECTAL DIAZEPAM Medicines Protocol RECTAL DIAZEPAM RECTAL DIAZEPAM v2.0 1/6 Protocol Details Version 2.0 Legal category Staff grades POM Registered Paramedic Registered Nurse Specialist Paramedic (Urgent and Emergency

More information

Etopan XL 600 mg tablets

Etopan XL 600 mg tablets Package leaflet: Information for the user Etopan XL 600 mg tablets etodolac Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. Keep

More information

Patient Group Direction for LIDOCAINE INJECTION (Version 02) Valid From 1 October September 2019

Patient Group Direction for LIDOCAINE INJECTION (Version 02) Valid From 1 October September 2019 Version Control This PGD has been agreed by the following organisations FCMS PDS Medical Doncaster CCG Lancashire CCGs including East Lancashire, Fylde and Wyre and North Lancashire CCGs Change history

More information

DEXOMEN 25 mg film-coated tablets

DEXOMEN 25 mg film-coated tablets PACKAGE LEAFLET: INFORMATION FOR THE USER DEXOMEN 25 mg film-coated tablets DEXKETOPROFEN This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for a medicine,

More information

Patient Group Direction for SALBUTAMOL INHALER (Version 02) Valid From 1 October September 2019

Patient Group Direction for SALBUTAMOL INHALER (Version 02) Valid From 1 October September 2019 Version Control This PGD has been agreed by the following organisations FCMS PDS Medical Doncaster CCG Lancashire CCGs including East Lancashire, Fylde and Wyre and North Lancashire CCGs Change history

More information

Name Brufen Flu Tablets & Suspension Description For the relief of the symptoms of colds and flu. Active Ingredients:

Name Brufen Flu Tablets & Suspension Description For the relief of the symptoms of colds and flu. Active Ingredients: Name Brufen Flu Tablets & Suspension Description For the relief of the symptoms of colds and flu Active Ingredients: Brufen Flu each tablet (Film-coated) contains: Ibuprofen 200 mg Pseudoephedrine hydrochloride

More information

PATIENT GROUP DIRECTION

PATIENT GROUP DIRECTION PATIENT GROUP DIRECTION FOR THE SUPPLY OF VARENICLINE (CHAMPIX ) TO ADULTS OVER 18 YEARS OF AGE BY COMMUNITY PHARMACISTS UNDER THE PUBLIC HEALTH SERVICE - SMOKING CESSSATION SERVICE IN NHS HIGHLAND THE

More information

Package leaflet: Information for the patient. Acetylsalicylic acid Bluefish 75 mg tablets Acetylsalicylic acid Bluefish 160 mg tablets

Package leaflet: Information for the patient. Acetylsalicylic acid Bluefish 75 mg tablets Acetylsalicylic acid Bluefish 160 mg tablets Package leaflet: Information for the patient Acetylsalicylic acid Bluefish 75 mg tablets Acetylsalicylic acid Bluefish 160 mg tablets Acetylsalicylic acid Read all of this leaflet carefully before you

More information

PATIENT INFORMATION LEAFLET FENOPINE 200MG, 400MG, & 600MG FILM-COATED TABLETS Ibuprofen

PATIENT INFORMATION LEAFLET FENOPINE 200MG, 400MG, & 600MG FILM-COATED TABLETS Ibuprofen PATIENT INFORMATION LEAFLET FENOPINE 200MG, 400MG, & 600MG FILM-COATED TABLETS Ibuprofen Read all of this leaflet carefully before you start taking this medicine. - Keep this leaflet. You may need to read

More information

Ketorolac injection. Supportive care

Ketorolac injection. Supportive care Supportive care Ketorolac injection Supportive care: specialist medicines This leaflet provides information on a medicine called ketorolac which is used to treat pain that is difficult to control. It is

More information

Job Title Name Signature Date. Director of Nursing Angela Wallace Signed Angela Wallace 30/6/2014

Job Title Name Signature Date. Director of Nursing Angela Wallace Signed Angela Wallace 30/6/2014 PATIENT GROUP DIRECTIONS FOR SUPPLY OF VARENICLINE (CHAMPIX ) BY AUTHORISED COMMUNITY PHARMACISTS WORKING IN FORTH VALLEY Protocol Number 445 Version 1 Date protocol prepared: June 2014 Date protocol due

More information

PATIENT GROUP DIRECTION FOR THE SUPPLY OF VARENICLINE (Champix ) BY COMMUNITY PHARMACISTS

PATIENT GROUP DIRECTION FOR THE SUPPLY OF VARENICLINE (Champix ) BY COMMUNITY PHARMACISTS PATIENT GROUP DIRECTION FOR THE SUPPLY OF VARENICLINE (Champix ) BY COMMUNITY PHARMACISTS Version No: Draft 2 Please note this PGD has been approved by SWYFT Drugs and Therapeutic Committee this is an

More information

NOTOPAIN CAPLETS. Diclofenac Sodium + Paracetamol. Composition. Each tablet contains: Diclofenac Sodium BP 50mg Paracetamol BP 500mg.

NOTOPAIN CAPLETS. Diclofenac Sodium + Paracetamol. Composition. Each tablet contains: Diclofenac Sodium BP 50mg Paracetamol BP 500mg. NOTOPAIN CAPLETS Diclofenac Sodium + Paracetamol Composition Each tablet contains: Diclofenac Sodium BP 50mg Paracetamol BP 500mg Pharmacology Phamacodynamics Diclofenac relieves pain and inflammation

More information

NALGESIN NALGESIN S 275 mg Film-coated tablets NALGESIN F 500 mg Film-coated tablets

NALGESIN NALGESIN S 275 mg Film-coated tablets NALGESIN F 500 mg Film-coated tablets PACKAGE LEAFLET: INFORMATION FOR THE USER NALGESIN NALGESIN S 275 mg Film-coated tablets NALGESIN F 500 mg Film-coated tablets NAPROXEN This leaflet is a copy of the Summary of Product Characteristics

More information

Patient Information Leaflet Lodine* SR Tablets 600mg (etodolac) 1. WHAT LODINE SR TABLETS ARE AND WHAT THEY ARE USED FOR

Patient Information Leaflet Lodine* SR Tablets 600mg (etodolac) 1. WHAT LODINE SR TABLETS ARE AND WHAT THEY ARE USED FOR Patient Information Leaflet Lodine* SR Tablets 600mg (etodolac) Read all of this leaflet carefully before you start using this medicine. Keep this leaflet. You may need to read it again. If you have any

More information

National Patient Group Direction for the Supply of Azithromycin, by Pharmacists, for the Treatment of Uncomplicated Chlamydia Infection

National Patient Group Direction for the Supply of Azithromycin, by Pharmacists, for the Treatment of Uncomplicated Chlamydia Infection National Patient Group Direction for the Supply of Azithromycin, by Pharmacists, for the Treatment of Uncomplicated Chlamydia Infection UNCONTROLLED WHEN PRINTED EFFECTIVE FROM NOVEMBER 2010 REVIEW DATE

More information

Patient Group Direction (PGD) Supply of Nitrofurantoin for uncomplicated Urinary Tract Infections in females aged 16 years and over

Patient Group Direction (PGD) Supply of Nitrofurantoin for uncomplicated Urinary Tract Infections in females aged 16 years and over Patient Group Direction (PGD) Supply of Nitrofurantoin for uncomplicated Urinary Tract Infections in females aged 16 years and over Version Control This document is only valid on the day it was printed

More information

Patient Group Direction for PROCHLORPERAZINE (Version 02) Valid From 1 October September 2019

Patient Group Direction for PROCHLORPERAZINE (Version 02) Valid From 1 October September 2019 Version Control This PGD has been agreed by the following organisations FCMS PDS Medical Doncaster CCG Lancashire CCGs including East Lancashire, Fylde and Wyre and North Lancashire CCGs Change history

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. EASOFEN MAX STRENGTH 400mg FILM-COATED TABLETS. Ibuprofen

PACKAGE LEAFLET: INFORMATION FOR THE USER. EASOFEN MAX STRENGTH 400mg FILM-COATED TABLETS. Ibuprofen PACKAGE LEAFLET: INFORMATION FOR THE USER EASOFEN MAX STRENGTH 400mg FILM-COATED TABLETS Ibuprofen Read all of this leaflet carefully before you start taking Easofen Max Strength Tablets because it contains

More information

Pronaxen 250 mg tablet OTC , Version 1.3 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN

Pronaxen 250 mg tablet OTC , Version 1.3 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN Pronaxen 250 mg tablet OTC 25.9.2015, Version 1.3 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Pronaxen 250 mg is indicated for

More information

SHARED CARE PRESCRIBING GUIDELINE

SHARED CARE PRESCRIBING GUIDELINE WORKING IN PARTNERSHIP East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG, Surrey Heath CCG, North East Hampshire & Farnham CCG, Crawley CCG, Horsham & Mid-Sussex CCG SHARED

More information

Package leaflet: Information for the user. Diklofenak T Actavis 25 mg mg film-coated tablets. diclofenac potassium

Package leaflet: Information for the user. Diklofenak T Actavis 25 mg mg film-coated tablets. diclofenac potassium PACKAGE LEAFLET Package leaflet: Information for the user Diklofenak T Actavis 25 mg mg film-coated tablets diclofenac potassium RX Read all of this leaflet carefully before you start taking this medicine

More information

CSP Nabumetone ES/H/PSUR/0014/001. January 2010

CSP Nabumetone ES/H/PSUR/0014/001. January 2010 CSP Nabumetone ES/H/PSUR/0014/001 January 2010 CLINICAL PARTICULARS 4.1 Therapeutic indications Nabumetone is indicated in the symptomatic treatment of a variety of musculoskeletal disorders requiring

More information

National Patient Group Direction for the Supply of Azithromycin, by Pharmacists, for the Treatment of Uncomplicated Chlamydia Infection

National Patient Group Direction for the Supply of Azithromycin, by Pharmacists, for the Treatment of Uncomplicated Chlamydia Infection National Patient Group Direction for the Supply of Azithromycin, by Pharmacists, for the Treatment of Uncomplicated Chlamydia Infection UNCONTROLLED WHEN PRINTED EFFECTIVE FROM OCTOBER 2008 REVIEW DATE

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. Diclac Relief 1% w/w Gel. Diclofenac Sodium

PACKAGE LEAFLET: INFORMATION FOR THE USER. Diclac Relief 1% w/w Gel. Diclofenac Sodium PACKAGE LEAFLET: INFORMATION FOR THE USER Diclac Relief 1% w/w Gel Diclofenac Sodium Read all of this leaflet carefully before you start using this medicine because it contains contains important information

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Melfen 200 mg Film-coated Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 200 mg ibuprofen. Excipients:

More information

PUBLIC SUMMARY OF RISK MANAGEMENT PLAN BURANA 40 MG/ML ORAL SUSPENSION DATE: , VERSION 1

PUBLIC SUMMARY OF RISK MANAGEMENT PLAN BURANA 40 MG/ML ORAL SUSPENSION DATE: , VERSION 1 PUBLIC SUMMARY OF RISK MANAGEMENT PLAN BURANA 40 MG/ML ORAL SUSPENSION DATE: 15-5-2015, VERSION 1 VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Musculoskeletal pain: Musculoskeletal

More information

NHS Lothian Patient Group Direction Version: 006

NHS Lothian Patient Group Direction Version: 006 PATIENT GROUP DIRECTION FOR THE ADMINISTRATION AND SUPPLY OF AZITHROMYCIN FOR TREATMENT OF CHLAMYDIA (PATIENT OR PARTNER) OR CONTACTS OF NON-SPECIFIC URETHRITIS (NSU) OR PELVIC INFLAMMATORY DISEASE (PID)

More information

Summary of Product Characteristics

Summary of Product Characteristics 1 NAME OF THE MEDICINAL PRODUCT Vitafen 100mg Film-coated Tablets Summary of Product Characteristics 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains Aceclofenac 100mg. For a full list of

More information

SUMMARY OF PRODUCT CHARACTERISTICS 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

SUMMARY OF PRODUCT CHARACTERISTICS 2 QUALITATIVE AND QUANTITATIVE COMPOSITION SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Ibuprofen 200mg Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains Ibuprofen 200mg. Also contains lactose, sucrose

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. Disprin Extra Strength 500mg Effervescent Tablets. ASPIRIN (acetylsalicylic acid)

PACKAGE LEAFLET: INFORMATION FOR THE USER. Disprin Extra Strength 500mg Effervescent Tablets. ASPIRIN (acetylsalicylic acid) PACKAGE LEAFLET: INFORMATION FOR THE USER Disprin Extra Strength 500mg Effervescent Tablets ASPIRIN (acetylsalicylic acid) Read all of this leaflet carefully before you start taking this medicine because

More information

PATIENT GROUP DIRECTIONS FOR SUPPLY OF VARENICLINE (CHAMPIX ) BY AUTHORISED COMMUNITY PHARMACISTS WORKING IN TAYSIDE

PATIENT GROUP DIRECTIONS FOR SUPPLY OF VARENICLINE (CHAMPIX ) BY AUTHORISED COMMUNITY PHARMACISTS WORKING IN TAYSIDE PATIENT GROUP DIRECTIONS FOR SUPPLY OF VARENICLINE (CHAMPIX ) BY AUTHORISED COMMUNITY PHARMACISTS WORKING IN TAYSIDE GENERAL POLICY 2 PATIENT GROUP DIRECTIONS FOR SUPPLY OF VARENICLINE 4 STANDING ORDER

More information

Expiry Date: July 2009 Template Version: Page 1 of 7

Expiry Date: July 2009 Template Version: Page 1 of 7 Salbutamol nebules YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT NPGD2007/355 (supersedes 2004/177) Clinical Condition Indication: Inclusion

More information

Document Details Patient Group Direction Hepatitis A vaccine (Havrix Monodose ) Trust Ref No Local Ref (optional) Main points the

Document Details Patient Group Direction Hepatitis A vaccine (Havrix Monodose ) Trust Ref No Local Ref (optional) Main points the Document Details Title Patient Group Direction Hepatitis A vaccine (Havrix Monodose ) Trust Ref No 1506-41174 Local Ref (optional) Main points the Active immunisation against infection caused by Hepatitis

More information

Clinician Responsible for Training and Review: Emergency Department Consultant

Clinician Responsible for Training and Review: Emergency Department Consultant Patient Group Direction for the supply and/or administration of Paracetamol Oral Suspension 250mg/5ml (Paracetamol paediatric suspension) to children receiving treatment from NHS Borders services. This

More information

Essential Shared Care Agreement Drugs for Dementia

Essential Shared Care Agreement Drugs for Dementia E098 Essential Shared Care Agreement Drugs for Dementia Please complete the following details: Patient s name, address, date of birth Consultant s contact details (p.3) And send One copy to: 1. the patient

More information

Prescribing Guidelines Prescribing arrangement for the management of patients transferring from Secondary Care to Primary Care

Prescribing Guidelines Prescribing arrangement for the management of patients transferring from Secondary Care to Primary Care Berkshire West Integrated Care System Representing Berkshire West Clinical Commisioning Group Royal Berkshire NHS Foundation Trust Berkshire Healthcare NHS Foundation Trust Berkshire West Primary Care

More information

COMPOSITION: Each film-coated tablet contains 500mg mefenamic acid. Also includes sunset yellow E110. See leaflet for further information.

COMPOSITION: Each film-coated tablet contains 500mg mefenamic acid. Also includes sunset yellow E110. See leaflet for further information. Mefac 500mg Film-coated Tablets Mefenamic acid 100 Film-coated Tablets PA Holder: Rowa Pharmaceuticals Ltd., Bantry Co. Cork, Ireland PA 74/15/2 Marketed by: Rowex Ltd., Bantry, Co. Cork, Ireland COMPOSITION:

More information

Boots Fever and Pain Relief 6 Months Plus Ibuprofen 100 mg/5 ml Suspension

Boots Fever and Pain Relief 6 Months Plus Ibuprofen 100 mg/5 ml Suspension Information for the user Boots Fever and Pain Relief 6 Months Plus Ibuprofen 100 mg/5 ml Suspension Read all of this leaflet carefully because it contains important information for you. This medicine is

More information

EFFECTIVE SHARED CARE AGREEMENT (ESCA)

EFFECTIVE SHARED CARE AGREEMENT (ESCA) EFFECTIVE SHARED CARE AGREEMENT (ESCA) DRUG NAME: HYDROXYCHLOROQUINE INDICATION/S COVERED: active rheumatoid arthritis, juvenile idiopathic arthritis, discoid and systemic lupus erythematosus Coastal West

More information

Migraine Relief Film-coated Tablets ibuprofen lysine

Migraine Relief Film-coated Tablets ibuprofen lysine PACKAGE LEAFLET 1 Package leaflet: Information for the user Migraine Relief Film-coated Tablets ibuprofen lysine Read all of this leaflet carefully before you start taking this medicine because it contains

More information

Essential Shared Care Agreement Drugs for Dementia

Essential Shared Care Agreement Drugs for Dementia Ref No. E052 Please complete the following details: Patient s name, address, date of birth Consultant s contact details (p.3) And send One copy to: 1. the patient s GP 2. put one copy in care plan 3. give

More information

NEW ZEALAND DATA SHEET

NEW ZEALAND DATA SHEET IBUPROFEN (Arrowcare) Ibuprofen Tablets 200mg Presentation NEW ZEALAND DATA SHEET White, capsule shaped, coated tablets with no markings. Uses Actions Ibuprofen is a non-steroidal anti-inflammatory agent.

More information

Developed By Name Signature Date

Developed By Name Signature Date Patient Group Direction 2156 version 2.0 Administration of Ipratropium 250mcg/ml Nebuliser Solution in Acute Asthma by Registered Practitioners employed by Torbay and South Devon NHS Foundation Date of

More information

PRODUCT INFORMATION. Sudafed* Sinus + Anti-inflammatory Pain Relief Caplets

PRODUCT INFORMATION. Sudafed* Sinus + Anti-inflammatory Pain Relief Caplets PRODUCT INFORMATION Sudafed* Sinus + Anti-inflammatory Pain Relief Caplets Product description Sudafed* Sinus + Anti-inflammatory Pain Relief caplets contain pseudoephedrine hydrochloride 30 mg and ibuprofen

More information

Shared Care Agreement for Donepezil

Shared Care Agreement for Donepezil ESCA: for the treatment of Alzheimer s disease SECONDARY CARE SECTION TO BE COMPLETED BY INITIATING DOCTOR Patient s Name: Date of Birth: NHS Number: ESCA Date: One copy of information leaflet given to

More information

Package leaflet: Information for the user MELFEN 200mg FILM-COATED TABLETS MELFEN 400mg FILM-COATED TABLETS. Ibuprofen

Package leaflet: Information for the user MELFEN 200mg FILM-COATED TABLETS MELFEN 400mg FILM-COATED TABLETS. Ibuprofen Package leaflet: Information for the user MELFEN 200mg FILM-COATED TABLETS MELFEN 400mg FILM-COATED TABLETS Ibuprofen Read all of this leaflet carefully before you start taking this medicine because it

More information

Package Insert. Spasfree

Package Insert. Spasfree Package Insert Spasfree Product Summary 1. Name of the medicinal product Spasfree 2. Qualitative and quantitative composition Each film-coated tablet contains Aceclofenac 100 mg and drotaverine hydrochloride

More information

IMMEDIATE DICLOFENAC NEW CONTRAINDICATIONS AND WARNINGS AFTER A EUROPE-WIDE REVIEW OF CARDIOVASCULAR SAFETY

IMMEDIATE DICLOFENAC NEW CONTRAINDICATIONS AND WARNINGS AFTER A EUROPE-WIDE REVIEW OF CARDIOVASCULAR SAFETY Finance, EHealth and Pharmaceuticals Directorate Pharmacy and Medicines Division T: 0131-244 2528 E: irene.fazakerley@scotland.gsi.gov.uk 1. Medical Directors 2. Directors of Public Health 3. Directors

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. Flarin 200 mg Soft Capsules Ibuprofen

PACKAGE LEAFLET: INFORMATION FOR THE USER. Flarin 200 mg Soft Capsules Ibuprofen PACKAGE LEAFLET: INFORMATION FOR THE USER Flarin 200 mg Soft Capsules Ibuprofen Read all of this leaflet carefully before you start taking this product. This medicine is available without prescription.

More information

Diclofenac, Version 1.2. Elements for a public summary. VI.2.1 Overview of disease epidemiology

Diclofenac, Version 1.2. Elements for a public summary. VI.2.1 Overview of disease epidemiology VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology It has been estimated that one in five adults suffer from pain worldwide, and one in ten adults are diagnosed with pain each year.

More information

RANTUDIL F 60mg capsules

RANTUDIL F 60mg capsules PACKAGE LEAFLET: INFORMATION FOR THE USER RANTUDIL F 60mg capsules ACEMETACIN This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for a medicine, which outlines

More information

Patient Group Direction for the Supply of Varenicline (Champix ) by Authorised Community Pharmacists

Patient Group Direction for the Supply of Varenicline (Champix ) by Authorised Community Pharmacists Patient Group Direction for the Supply of Varenicline (Champix ) This Patient Group Direction (PGD) is a specific written instruction for the supply of varenicline to groups of patients who may not be

More information

PATIENT GROUP DIRECTION (PGD) FOR THE ADMINISTRATION OF ORAL DIAZEPAM TO WORKING AGE AND OLDER PEOPLE IN THE COMMUNITY

PATIENT GROUP DIRECTION (PGD) FOR THE ADMINISTRATION OF ORAL DIAZEPAM TO WORKING AGE AND OLDER PEOPLE IN THE COMMUNITY PATIENT GROUP DIRECTION (PGD) FOR THE ADMINISTRATION OF ORAL DIAZEPAM TO WORKING AGE AND OLDER PEOPLE IN THE COMMUNITY Version Number: 5 Patient Group Direction drawn up by: Name Ray Lyon Dr Al Amaladoss

More information

Advil Liqui - gels 200 Capsules

Advil Liqui - gels 200 Capsules 1. NAME OF THE MEDICINAL PRODUCT Advil Liqui - gels 200 Capsules 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains 200mg Ibuprofen For excipients, see 6.1 3. PHARMACEUTICAL FORM Capsules

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Melfen 400 mg Film-coated Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 400 mg ibuprofen. For the

More information

Patient Group Direction for the Supply of Nitrofurantoin MR 100mg capsules

Patient Group Direction for the Supply of Nitrofurantoin MR 100mg capsules October 2016 Patient Group Direction for the Supply of Nitrofurantoin MR 100mg capsules This Patient Group Direction (PGD) is a specific written instruction for the supply and/or administration of nitrofurantoin

More information

Patient Group Direction for PREDNISOLONE (Version 02) Valid From 1 October September 2019

Patient Group Direction for PREDNISOLONE (Version 02) Valid From 1 October September 2019 Version Control This PGD has been agreed by the following organisations FCMS PDS Medical Doncaster CCG Lancashire CCGs including East Lancashire, Fylde and Wyre and North Lancashire CCGs Change history

More information

Effective Shared Care Agreement (ESCA) for drugs used in dementia- Donepezil, Galantamine, Rivastigmine and Memantine

Effective Shared Care Agreement (ESCA) for drugs used in dementia- Donepezil, Galantamine, Rivastigmine and Memantine Effective Shared Care Agreement (ESCA) for drugs used in dementia- Donepezil, Galantamine, Rivastigmine and Memantine for the treatment of dementia AREAS OF RESPONSIBILITY FOR THE SHARING OF CARE This

More information

Community Psychiatric Nurse. Consultant Psychiatrist, Substance Misuse Services

Community Psychiatric Nurse. Consultant Psychiatrist, Substance Misuse Services PATIENT GROUP DIRECTION (PGD) FOR THE ADMINISTRATION OF HEPATITIS A VACCINE (HAVRIX MONODOSE VACCINE) BY REGISTERED NURSES WORKING IN THE COMMUNITY SUBSTANCE MISUSE TEAMS Version Number : 2 Patient Group

More information

PATIENT INFORMATION LEAFLET. Nu-Seals 75mg Gastro-resistant Tablets aspirin (acetylsalicylic acid)

PATIENT INFORMATION LEAFLET. Nu-Seals 75mg Gastro-resistant Tablets aspirin (acetylsalicylic acid) PATIENT INFORMATION LEAFLET Nu-Seals 75mg Gastro-resistant Tablets aspirin (acetylsalicylic acid) Read all of this leaflet carefully before you start taking this medicine because it contains important

More information

DEXOMEN 25 mg granules for oral solution

DEXOMEN 25 mg granules for oral solution PACKAGE LEAFLET: INFORMATION FOR THE USER DEXOMEN 25 mg granules for oral solution DEXKETOPROFEN This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for a medicine,

More information

Document Details. Patient Group Direction

Document Details. Patient Group Direction Document Details Title Patient Group Direction (PGD) Hepatitis B Vaccine (Engerix ) Trust Ref No 1505-41182 Local Ref (optional) Main points the Immunisation against Hepatitis B document covers Who is

More information

Clinician Responsible for Training and Review: Emergency Department Consultant

Clinician Responsible for Training and Review: Emergency Department Consultant Patient Group Direction for the Supply of Salbutamol Inhaler to patients receiving treatment from NHS Borders Emergency Department/Out of Hours/Minor Injury Units This document authorises the supply or

More information

Patient Group Direction for GLUCAGON (Version 02) Valid From 1 October September 2019

Patient Group Direction for GLUCAGON (Version 02) Valid From 1 October September 2019 Version Control This PGD has been agreed by the following organisations FCMS Doncaster CCG Lancashire CCGs including East Lancashire, Fylde and Wyre and North Lancashire CCGs Change history 31/07/17 V02

More information

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

2. QUALITATIVE AND QUANTITATIVE COMPOSITION SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Ibuprofen 200 mg Tablets Lloyds pharmacy Ibuprofen 200mg Caplets Ibuprofen 200 mg Caplets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

More information

Clinical Condition Indication:

Clinical Condition Indication: GG&C PGD ref no: 2012/943 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: For active immunisation of individuals

More information

PATIENT INFORMATION LEAFLET. Nu-Seals 75 aspirin (acetylsalicylic acid)

PATIENT INFORMATION LEAFLET. Nu-Seals 75 aspirin (acetylsalicylic acid) PATIENT INFORMATION LEAFLET Nu-Seals 75 aspirin (acetylsalicylic acid) Read all of this leaflet carefully before you start taking this medicine Keep this leaflet. You may need to read it again. If you

More information

Prescribing Framework for Methotrexate for Immunosuppression in ADULTS

Prescribing Framework for Methotrexate for Immunosuppression in ADULTS Hull & East Riding Prescribing Committee Prescribing Framework for Methotrexate for Immunosuppression in ADULTS Patient s Name:.. NHS Number: Patient s Address:... (Use addressograph sticker) GP s Name:...

More information

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Piroxicam 20mg Capsules 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains 20mg of Piroxicam. For a full list of excipients,

More information

PRESCRIBING GUIDANCE METHOTREXATE for the treatment of vasculitis

PRESCRIBING GUIDANCE METHOTREXATE for the treatment of vasculitis PRESCRIBING GUIDANCE METHOTREXATE for the treatment of vasculitis For the latest information on interactions and adverse effects, always consult the latest version of the Summary of Product Characteristics

More information

PATIENT GROUP DIRECTIONS FOR SUPPLY OF VARENICLINE (CHAMPIX ) BY AUTHORISED COMMUNITY PHARMACISTS WORKING IN NHS LANARKSHIRE

PATIENT GROUP DIRECTIONS FOR SUPPLY OF VARENICLINE (CHAMPIX ) BY AUTHORISED COMMUNITY PHARMACISTS WORKING IN NHS LANARKSHIRE PATIENT GROUP DIRECTIONS FOR SUPPLY OF VARENICLINE (CHAMPIX ) BY AUTHORISED COMMUNITY PHARMACISTS WORKING IN NHS LANARKSHIRE (Approved May 2014 - Review Date May 2016) GENERAL POLICY PATIENT GROUP DIRECTION

More information

Please note that the information highlighted in grey colour is the additional information specific to the concerned dosage form.

Please note that the information highlighted in grey colour is the additional information specific to the concerned dosage form. Proposed Core Safety Profile for diclofenac systemic formulations, including solution for injection, sugar-coated tablets, prolonged release tablets, dispersible tablets, gastro-resistant tablets and suppositories

More information

Package Leaflet: Information for the Patient Diclofenac 75 mg / 3 ml Solution for Injection Diclofenac Sodium

Package Leaflet: Information for the Patient Diclofenac 75 mg / 3 ml Solution for Injection Diclofenac Sodium Package Leaflet: Information for the Patient Diclofenac 75 mg / 3 ml Solution for Injection Diclofenac Sodium Read all of this leaflet carefully before you are given this medicine because it contains important

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Ibuprofen 200 mg Caplets Ibuprofen 200 mg Tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 200mg of Ibuprofen.

More information